Adheron Therapeutics Acquired By Roche For $105M
Berkeley-based Adheron Therapeutics has been acquired by Roche, in a deal worth $105M in an upfront payment, plus earnout worth up to an additional $475M. Adheron Therapeutics develops technology that disrupts immune cell adhesion, which is being applied to treatments for inflammatory and autoimmune diseases, including rheumatoid arthritis. Adheron Threapeutics is led by Hari Kumar, and was venture backed by Health Care Ventures, MedImmune Ventures, Partners Innovation Fund, Amgen Ventures, and SROne.
posted on Friday, October 9, 2015
Related companies:
Adheron Therapeutics, Inc.
Related stories:
> Bina Technologies Acquired By Roche
> Roche Acquires THP
> CytomX Therapeutics Raises $41M
> SV Life Sciences Names New Venture Partner
> Alios BioPharma Gains $8.4M
silicontap.com Home